ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma

Abstract

Background

Treatment outcome for hepatocellular carcinoma (HCC) is related to tumor burden and liver function. Grading systems assessing liver function need validation in different clinical settings.

Purpose

To evaluate drug-eluting embolic transarterial chemoembolization (DEE-TACE) in Child–Pugh A HCC with respect to albumin-bilirubin (ALBI) and platelet-albumin-bilirubin (P-ALBI) grade.

Material and Methods

Forty-nine patients with Child–Pugh class A, diagnosed with HCC and allocated to DEE-TACE treatment, were retrospectively analyzed regarding tumor and treatment characteristics, radiological response (mRECIST) one month post treatment, overall survival (OS), and adverse events (AEs; CTCAE, grades ≥3) with respect to ALBI and P-ALBI grade.

Results

There were 21 ALBI 1 patients, 29 P-ALBI 1 patients, and 19 patients were both ALBI and P-ALBI 1. Objective response rate was 74% with no statistically significant difference for ALBI (1 vs. 2; P = 0.08), or P-ALBI (1 vs. 2; P = 0.49). OS was 14.8 months (range = 1.7–62.0; ALBI 1 vs. 2: P = 0.08; P-ALBI 1 vs. 2: P = 0.003). OS in responders with ALBI 1 and 2 was 28.9 vs.10.2 months (P = 0.02), and P-ALBI 1 and 2 was 26.7 vs. 8.6 months (P < 0.001). In multivariate analyses, both ALBI 2 (HR = 2.4, P = 0.02) and P-ALBI 2 (HR = 3.3, P < 0.01) were negative prognostic factors for survival. There were 15 AEs in 13 patients, with hepatic failure only occurring in ALBI 2 and P-ALBI 2 patients.

Conclusion

P-ALBI grade 1 and 2 differentiated survival in Child–Pugh A patients treated with DEE-TACE. Both grading systems can differentiate survival in patients responding to treatment.

Keywords

DEE-TACE hepatocellular carcinoma mRECIST overall survival ALBI grade P-ALBI grade adverse events

Get full access to this article

View all access options for this article.

References

European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908–943.

Pugh

RNH

Murray-Lyon

Dawson

et al . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646–649.

Johnson

Berhane

Kagebayashi

et al . Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33:550–558.

Knox

JJ.

Addressing the interplay of liver disease and hepatocellular carcinoma on patient survival: the ALBI scoring model.

J Clin Oncol 2015; 33:529–531.

Chan

Kumada

Toyoda

et al . Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol 2016; 31:1300–1306.

Roayaie

S JG

Berhane

Tabrizian

et al . PALBI-An Objective Score Based on Platelets, Albumin & Bilirubin Stratifies HCC Patients Undergoing Resection & Ablation Better than Child's Classification. The Liver Meeting. American Association for the Study of Liver Diseases 2015.

Liu

Hsu

Hsia

et al . ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol 2017; 32:879–886.

Yamada

Sato

Kawabata

et al . Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148:397–401.

Wang

De Baere

Idee

et al . Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015; 27:96–121.

10.

de Baere

Arai

Lencioni

et al . Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol 2016; 39:334–343.

11.

Lencioni

de Baere

Burrel

et al . Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012; 35:980–985.

12.

Carter

Martin II

RC.

Drug-eluting bead therapy in primary and metastatic disease of the liver.

HPB (Oxford) 2009; 11:541–550.

13.

Lewis

Dreher

MR.

Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy.

J Control Release 2012; 161:338–350.

14.

Tang

Taylor

Gonzalez

et al . Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. J Control Release 2006; 116:55–56.

15.

Lammer

Malagari

Vogl

et al . Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41–52

16.

Waked

Berhane

Toyoda

et al . Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer 2017; 116:448–454.

17.

Hansmann

Evers

Bui

et al . Albumin-bilirubin and platelet-albumin-bilirubin grades accurately predict overall survival in high-risk patients undergoing conventional transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2017; 28:1224–1231.

18.

Hickey

Mouli

Kulik

et al . Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2016; 27:795–802.

19.

Pinato

Sharma

Allara

et al . The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 2017; 66:338–346.

20.

Golfieri

Giampalma

Renzulli

et al . Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111:255–264.

21.

Lencioni

Llovet

JM.

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Semin Liver Dis 2010; 30:52–60.

22.

Gaba

Lewandowski

Hickey

et al . Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2016; 27:457–473.

23.

National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/ (accessed 15 August 2017).

24.

Gorodetski

Chapiro

Schernthaner

et al . Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2017; 27:526–535.

25.

Ray

Jr Brown

Green

et al . Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization. Am J Roentgenol 2015; 204:440–447.

26.

Hsu

Liu

Lee

et al . Hepatocellular carcinoma patients with performance status 1 deserve new classification and treatment algorithm in the BCLC system. Medicine (Baltimore) 2015; 94:1223.

27.

Brown

Gonen

et al . Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 2016; 34:2046–2053.

28.

Eskesen

Bjoro

Aandahl

et al . Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway–a population-based cohort study. Cancer Epidemiol 2014; 38:741–747.

29.

Alkofer

Lepennec

Chiche

Hepatocellular cancer in the non-cirrhotic liver.

J Visc Surg 2011; 148:3–11.

30.

Schutte

Schulz

Poranzke

et al . Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol 2014; 14:117.

31.

Trevisani

Frigerio

Santi

et al . Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010; 42:341–347.

32.

Kim

Jeong

et al . Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Intervent Radiol 2002; 25:270–274.

33.

Guiu

Deschamps

Aho

et al . Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 2012; 56:609–617.

34.

Gaba

Lokken

Hickey

et al . Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol 2017; 28:1210–1213.